SIMLANDI: Product Quality
Last updated
Summary
Product
SIMLANDI
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| SIMLANDI | SIMILANDI (PREFILLED SYRINGE) | DIN 02523949 | Solution | adalimumab injection 40mg / 0.4mL (pre-filled syringe) | 1917469A |
| SIMLANDI | SIMILANDI (AUTO-INJECTOR) | DIN 02523957 | Solution | adalimumab injection 40mg / 0.4mL (auto-injector) | IL220019, IL220023, IL220028, IL220036, IL220037, IL220042, IL220043 |
Issue
The affected lot contains an additional excipient (Phosphate Buffer). |
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Jamp Pharma Corporation.
1310 rue Nobel,
Boucherville, QC,
J4B 5H3
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-73528
Get notified
Receive emails about new and updated recall and safety alerts.